Sagimet Biosciences (SGMT) Research & Development (2022 - 2026)

Sagimet Biosciences' Research & Development history runs 5 years deep, the most recent figure standing at $7.0 million for Q1 2026.

• On a quarterly basis, Research & Development fell 54.41% year-over-year to $7.0 million in Q1 2026; TTM through Mar 2026 was $30.7 million, a 36.72% decrease from a year earlier, with the FY2025 full-year figure at $39.1 million, up 1.59% from the prior year.
• Research & Development climbed to $7.0 million in Q1 2026 per SGMT's latest filing, from $6.7 million in the prior quarter.
• Across five years, Research & Development topped out at $15.3 million in Q1 2025 and bottomed at $4.5 million in Q1 2023.
• The 5-year median for Research & Development is $6.6 million (2022), against an average of $7.7 million.
• Across the five-year window, Research & Development surged 191.56% in 2025 and slumped 54.41% in 2026, its largest moves.
• Year by year, Research & Development stood at $5.8 million in 2022, then dropped by 3.27% to $5.7 million in 2023, then soared by 151.34% to $14.2 million in 2024, then slumped by 52.63% to $6.7 million in 2025, then increased by 3.88% to $7.0 million in 2026.
• Per Business Quant, the three latest SGMT Research & Development figures stand at $7.0 million (Q1 2026), $6.7 million (Q4 2025), and $9.7 million (Q3 2025).